Janux Therapeutics Inc (JANX)

$27.35 +2.45 (9.84%)
Market Cap 1.50B
Revenue (ttm) 10.59M
Net Income (ttm) -68.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -651.46%
Debt to Equity Ratio 0.00
Volume 1,117,900
Avg Vol 799,648
Day's Range N/A - N/A
Shares Out 60.09M
Stochastic %K 13%
Beta 2.82
Analysts Strong Sell
Price Target $81.20

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 751 4493
Address:
10955 Vista Sorrento Parkway, Suite 200, San Diego, United States
judgeyoung2
judgeyoung2 Oct. 27 at 9:08 PM
$JANX why is it up after hours
0 · Reply
RunnerSignals
RunnerSignals Oct. 27 at 8:37 PM
$DQ $DSGN $SNAL $ARQQ $JANX finally shake off the sideways blues with big moves and strong volume
0 · Reply
Optionking828
Optionking828 Oct. 27 at 8:20 PM
$JANX news? Come on
1 · Reply
Milanfinest
Milanfinest Oct. 27 at 6:48 PM
$JANX ready?✈️
0 · Reply
judgeyoung2
judgeyoung2 Oct. 27 at 4:49 PM
$JANX data coming soon
1 · Reply
Optionking828
Optionking828 Oct. 27 at 3:50 PM
$JANX no one falling for this… let’s see what this bs is about
0 · Reply
Ralphbeach
Ralphbeach Oct. 27 at 11:13 AM
$DYN $BHVN $JANX
0 · Reply
directorwalsh
directorwalsh Oct. 24 at 1:44 AM
$JANX absolute hammer right here. The pronoun money has yet again sold off high risk bios that were undervalued in the first place. Long
0 · Reply
TheHacDay
TheHacDay Oct. 23 at 8:00 PM
$JANX Are we going bankrupt??
1 · Reply
Theflash88
Theflash88 Oct. 23 at 7:59 PM
$JANX
0 · Reply
Latest News on JANX
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:01 PM EDT - 2 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 31, 2025, 12:01 AM EDT - 3 months ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 24, 2025, 4:05 PM EDT - 3 months ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Jul 17, 2025, 4:30 PM EDT - 3 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 15, 2025, 8:00 AM EDT - 5 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:01 PM EDT - 6 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

May 5, 2025, 8:30 AM EDT - 6 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Apr 5, 2025, 8:14 AM EDT - 7 months ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 8 months ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 24, 2025, 4:01 PM EST - 9 months ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 8, 2025, 9:00 AM EST - 10 months ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 10 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 6, 2024, 7:43 PM EST - 11 months ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 4, 2024, 11:12 PM EST - 11 months ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 4:01 PM EST - 11 months ago

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:49 AM EST - 11 months ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 3, 2024, 10:39 AM EST - 11 months ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Dec 2, 2024, 4:30 PM EST - 11 months ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 25, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 19, 2024, 1:23 AM EST - 1 year ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Announces Updates to Board of Directors

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 20, 2024, 1:44 PM EDT - 1 year ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 8, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 29, 2024, 1:22 AM EST - 1 year ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:15 PM EST - 1 year ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 5:00 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 27, 2024, 8:38 AM EST - 1 year ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 26, 2024, 4:05 PM EST - 1 year ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Feb 20, 2024, 8:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Jan 8, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 7, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jul 17, 2023, 8:45 AM EDT - 2 years ago

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Jun 5, 2023, 4:35 PM EDT - 2 years ago

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Apr 24, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Apr 20, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 10, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Feb 14, 2023, 12:00 PM EST - 2 years ago

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Dec 27, 2022, 9:00 AM EST - 3 years ago

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Janux Therapeutics to Present at Upcoming Investor Conferences in November

Nov 22, 2022, 6:00 AM EST - 3 years ago

Janux Therapeutics to Present at Upcoming Investor Conferences in November

judgeyoung2
judgeyoung2 Oct. 27 at 9:08 PM
$JANX why is it up after hours
0 · Reply
RunnerSignals
RunnerSignals Oct. 27 at 8:37 PM
$DQ $DSGN $SNAL $ARQQ $JANX finally shake off the sideways blues with big moves and strong volume
0 · Reply
Optionking828
Optionking828 Oct. 27 at 8:20 PM
$JANX news? Come on
1 · Reply
Milanfinest
Milanfinest Oct. 27 at 6:48 PM
$JANX ready?✈️
0 · Reply
judgeyoung2
judgeyoung2 Oct. 27 at 4:49 PM
$JANX data coming soon
1 · Reply
Optionking828
Optionking828 Oct. 27 at 3:50 PM
$JANX no one falling for this… let’s see what this bs is about
0 · Reply
Ralphbeach
Ralphbeach Oct. 27 at 11:13 AM
$DYN $BHVN $JANX
0 · Reply
directorwalsh
directorwalsh Oct. 24 at 1:44 AM
$JANX absolute hammer right here. The pronoun money has yet again sold off high risk bios that were undervalued in the first place. Long
0 · Reply
TheHacDay
TheHacDay Oct. 23 at 8:00 PM
$JANX Are we going bankrupt??
1 · Reply
Theflash88
Theflash88 Oct. 23 at 7:59 PM
$JANX
0 · Reply
Theflash88
Theflash88 Oct. 23 at 7:57 PM
$JANX I added…
0 · Reply
CooperHandy
CooperHandy Oct. 23 at 7:38 PM
$JANX Come on JANX… why you gotta be like that 😭😂
0 · Reply
TheHacDay
TheHacDay Oct. 23 at 7:17 PM
$JANX Why??
0 · Reply
Optionking828
Optionking828 Oct. 23 at 5:24 PM
$JANX zero communication
0 · Reply
Optionking828
Optionking828 Oct. 23 at 3:56 PM
$JANX
0 · Reply
ZUffisift
ZUffisift Oct. 21 at 2:30 PM
$JANX missed the whole bull market .. remarkable
1 · Reply
Optionking828
Optionking828 Oct. 20 at 8:09 PM
$JANX time for announcement
0 · Reply
Optionking828
Optionking828 Oct. 20 at 1:15 PM
$JANX time from a comeback
0 · Reply
Twocyprus6
Twocyprus6 Oct. 17 at 10:30 PM
$JANX what’s the catalyst for this one?
0 · Reply
BioStick123
BioStick123 Oct. 16 at 1:15 AM
$JANX moving ahead of data. $35 soon 🦉
2 · Reply
CooperHandy
CooperHandy Oct. 15 at 9:01 PM
$JANX 🔥
0 · Reply
Optionking828
Optionking828 Oct. 15 at 8:04 PM
$JANX beautiful close
0 · Reply